Fulminant hepatic failure is an uncommon but dramatic illness with a high mortality. Viral hepatitis or drug toxicity is the usual cause. In the severe forms of the illness the patients, often young and previously healthy, rapidly become profoundly unwell due to extensive hepatic necrosis. Coma is accompanied by a disastrous disturbance of all the synthetic, metabolic and excretory functions of the liver. Management is largely supportive and multisystem complications may demand all the resources of the intensive care unit to allow survival. Systems for temporary hepatic support have aroused interest, based on the assumption that the hepatic lesion is potentially reversible. A number of heroic techniques have been tried and abandoned. Encouraging reports of charcoal column haemoperfusion have yet to be confirmed by controlled clinical trial.
Liver failure may occur in patients with chronic parenchymal disease (usually cirrhosis) or it can develop suddenly as a result of massive necrosis of liver cells in previously fit patients -fulminant hepatic failure (FHF). This review will be restricted to the latter syndrome, defined as one in which signs of encephalopathy develop within eight weeks of the onset of symptoms in patients with a previously normal liver. 1 This separation of acute from chronic disease is of more than academic importance. For example, changes in conscious state may also occur in chronic liver disease but the pathogenesis of the condition, portal-systemic encephalopathy (PSE), a 'bypassed liver' syndrome, is less complicated and the causes are potentially more reversible. In contrast the severe forms of FHF, a 'failing liver' syndrome, present physicians with some of their most complex management problems. Coma is accompanied by metabolic chaos. AETIOLOGY Fulminant hepatic faih,ue is usually caused by viral hepatitis or drugs ( Table 2) . Fulminant viral hepatitis is almost always due to A, B or Non-A Non-B (NANB) or combinations of these infections. Occasionally, superinfection of hepatitis B carriers with the recently described delta virus 3 causes FHF, but this condition seems less common in Australia (where carriers of hepatitis B virus infection are fewer) than in Southern Europe. 4 Delta is an incomplete RNA nucleoprotein that depends on the hepatitis B genome for replication, and is then provided with a hepatitis B surface antigen (HBsAg) coat. Thus, the delta agent can only infect persons with acute or chronic hepatitis B virus infection and for only as long as that infection persists.
Fortunately, death from FHF is rare in acute viral hepatitis. In a series of 5547 patients admitted to Fairfield infectious diseases hospital, Melbourne, from 1971 to 1983,0.84070 died. The fatality rate for patients with hepatitis A was 0.14%; for patients with hepatitis B, 0.84%; and for patients with NANB hepatitis, 2.29%. 4 The high case fatality rate for NANB hepatitis may be a reflection of the lack of a specific diagnostic test and failure to recognise the many subclinical cases. 5 Delta antibody was not detected in any patient in this series. The highest fatality rates were seen in post-transfusion hepatitis B (18.8%), a disease now greatly reduced in incidence since the introduction of blood donor screening for HBsAg.
Apart from viral hepatitis which occurs worldwide, the incidence of other causes of FHF may vary from country to country. In the United Kingdom and Australia paracetamol overdose is an important cause, while in France Amanita phalloides toxicity constitutes an important aetiological agent. Since the first recorded case in 1966, paracetamol overdose (49%) has become the commonest cause of FHF in patients admitted to the liver unit, Kings College Hospital, London. 6 Viral hepatitis (38%) occurred in a minority of their patients, halothane-associated toxicity in 4%, pregnancy-associated FHF in 4%, with various rarities constituting the remainder ( Table 2) .
Paracetamol damages the liver through the formation of a highly reactive metabolite which is normally trapped and inactivated by preferential conjugation with hepatic glutathione. Following a single hepatotoxic dose (circa 250 mg/kg or more) glutathione is depleted and the toxic metabolite binds covalently to vital proteins and enzymes, causing cell damage and necrosis. Severe liver damage (plasma aminotransferase concentrations >1000 IU/l) occurs in about 60% of patients with paracetamol concentrations above a 'treatment line' joining semilogarithmic plots of 200 Jig/ml (1.3 mmol/l) at 4 hours and 30 Jig/ml (0.2 mmol/l) at 15 hours after ingestion 7 • Although recovery of liver function is usually rapid and complete, fulminant hepatic failure develops three to six days after ingestion in a small number of severely poisoned patients, and is often fatal. In large series of unselected patients taking paracetamol in overdosage, without specific treatment, severe liver damage occurred in about 8% and fatal hepatic failure in 1-4%.7 Mortality figures from specialist liver units, where the patients are highly selected, are higher but unrepresentative. The introduction of effective therapy for paracetamol poisoning (see below) has reduced morbidity and mortality. Since 1973 there have been no deaths at the Edinburgh Regional Poisoning Treatment Centre, Scotland, from paracetamol-induced hepatic failure in patients treated within ten hours of drug ingestion. Reye's syndrome is characterised by acute encephalopathy associated with cerebral oedema and fatty change in the viscera, especially the liver. 8 It is a disease of childhood, most common around the age of six years and is exceptionally rare in adults. It usually occurs one to two weeks after a respiratory illness or exanthem. Viruses such as chicken pox and influenza B, and toxins, including salicylates, have been postulated as important, but the exact causes are unknown. Deficiencies in mitochondrial enzymes of the urea cycle have been described (e.g. absent ornithine transcarbamylase), which explain many features of the syndrome.
The encephalopathy of Reye's syndrome is clinically similar to that of FHF but jaundice rarely occurs and serum bilirubin is usually less than 50 f../molll (3 mg/dl). High transaminases, coagulopathy, hypoglycaemia and hyperammonaemia are characteristic and all the complications of FHF may occur. The liver enlarges as the disease advances but improvement occurs in 7-10 days in the 40-50070 who survive. A small percentage of the survivors suffer permanent cerebral damage. PATHOLOGY Most causes of FHF give rise to widespread hepatic necrosis. The liver at autopsy weighs less than 1.0 kg (normally circa 1.5 kg), and shows little hepatocyte regeneration but often bile duct proliferation. Liver biopsies have been carried out soon after the onset of FHF and show that the extent of necrosis is related to the prognosis. 9 Hepatocytes normally constitute 85% of the total liver volume; no patient survived when this figure fell below 35%, while in those who regained consciousness hepatocytes constituted 45% or more of hepatic volume.
Some rare cases of FHF cause intense fatty change in the liver. These include the fatty degeneration of pregnancy, Reye's syndrome and tetracycline or alcohol poisoning. Cardiac failure causes severe hepatic congestion and necrosis.
CLINICAL FEATURES FHF is characterised by hepatic encephalopathy and there are many criteria for grading its severity. Table 3 gives the most widely accepted classification. The only initial findings may be pOQr concentration or mild drowsiness, but increasing confusion and disorientation develop as the patient becomes stuporose and lapses into coma. Convulsions may occur. Most patients are jaundiced when encephalopathy first becomes apparent, and become progressively more jaundiced. Vomiting is common but abdominal pain is rare. Fetor hepaticus is usually present, and clinically the liver shrinks as the patient deteriorates, becoming undetectable, even on percussion. Ascites develops in a minority of patients and abnormal neurological signs may occur. Loss of brain stem reflexes, e.g. the oculovestibular reflexes, indicates a poor prognosis. 1O Tachycardia, sweating, fever, hypotension and hyperventilation are common. Other findings related to the many complications of FHF ( Table 2 ) will be discussed below.
INVESTIGATIONS
Serum transaminases are always elevated early in the syndrome, frequently to high levels.
They give little indication of prognosis and fall with time irrespective of outcome. Serum bilirubin rises soon after the onset and intense cholestasis may occur, even in patients who recover. Serum albumin falls gradually but failure of hepatic synthesis of the coagulation factors 11, V, VII, IX and X with their short half-lives produces prolongation of prothrombin time at an early stage and is the best laboratory guide to the prognosis. Moderate increases in serum alpha-fetoprotein concentrations may occur later in the illness and have been thought to indicate improved prognosis." A polymorph leucocytosis is common, even in the absence of infection.
COMPLICA TIONS
Encephalopathy
The pathogenesis of encephalopathy in FHF is controversial. Table 4 illustrates some of the factors which have been implicated. Ammonium, mainly derived from protein metabolism in the gut, has traditionally been the leading villain but circulating blood levels correlate poorly with depth of coma. Furthermore, measures which reduce high levels are often ineffective in reversing coma in FHF. However, a number of lines of indirect Intracellular ammonium concentrations may be 18 times that in the extracellular fluid, and the alkalosis of FHF may facilitate entry of ammonium into cells. The high levels of glutamine and glutamate (cerebral metabolites of ammonia) in the CSF of patients with FHF may be linked to unbalanced neurotransmitter synthesis. Finally, the coma-producing potential of ammonium may be increased severalfold when presented with fatty acids and mercaptans. 12
A good deal of interest has been generated by the identification of an abnormal plasma amino acid profile in patients with FHF. Plasma concentrations of the aromatic amino acids are greatly increased while the concentrations of branched chain amino acids remain normal, Always abnormal possibly due to reduction in the circulating insulin: glucagon ratio. It has been suggested that these amino acid abnormalities are responsible for coma, as the aromatic amino acids are precursors of several of the cerebral neurotransmitters. The production of normal neurotransmitters such as dopamine may be reduced and false neurotransmitters such as octapamine generated. 13 Numerous other substances have been found in the circulation of patients with FHF and found to be cerebrally toxic in animals (Table  4 ). Their role in humans is largely speculative. The subject has recently been reviewed by Silk.14 Despite the uncertainty about its cause, it is clear that the severity of encephalopathy is closely related· to the prognosis in FHF ( Table 5 ). Its progress should be monitored daily by clinical means. The electroencephalogram provides valuable diagnostic and prognostic information, although the abnormalities found are not specifically distinguishable from those seen in other metabolic disorders. Treatment of the encephalopathy should be vigorous before vital cardiorespiratory reflexes are disturbed. Therapy is largely limited to measures designed to reduce blood ammonia. There is no convincing controlled data to show that correction of plasma amino acid profiles following administration of specifically formulated amino acid nitrogen, either enterally or parenterally, has any greater beneficial effect on mental state than standard therapeutic measures directed towards ammonia reduction. 14 Consequently, no nitrogenous substances are given orally or parenterally. Recent studies on patients with PSE have shown that complete nutritional formulations may be given parenterally 15 or enterallyl6 without adverse effect on mental state. This has not yet been demonstrated for FHF, and dextrose infusions continue to be the mainstay for nutritional support in this condition. To reduce nitrogenous bacterial products from the gut, neomycin 1-2 g orally is given six-hourly initially. An enema (80 ml of 50070 magnesium sulphate) is given and repeated whenever gastrointestinal haemorrhage occurs. Lactulose 20 ml eight-hourly acidifies the stool, has a cathartic effect, traps ammonia and tends to suppress the proteolytic bacterial flora. 17 The dose is adjusted to produce two to three bowel actions daily, without diarrhoea. Large doses of levodopa (5 g) orally can temporarily increase cerebral electrical activity and may improve the consciousness level 18 but the effect is transient and the drug is not routinely used.
Sedatives should be used as little as possible. Patients who are very restless or who develop convulsions may be given small doses (5 mg) of diazepam intravenously,19 even though its metabolism is reduced in patients with liver disease. Oxazepam can be metabolised normally despite hepatic parenchymal injury,20 but an injectable preparation is not available.
Cerebral oedema
Post mortem studies have demonstrated macro-and microscopic evidence of cerebral oedema in 50070 or more cases of FHp21 and it may be severe enough to kill the patient. It does not occur in PSE and highlights the differences in pathophysiology of the two conditions. It is not necessarily associated with generalised fluid retention 22 and was present in more than 80% of patients who failed to respond to haemodialysis. 23 It is clinically difficult to diagnose as the signs of its presence are similar to those of coma unassociated with cerebral oedema.
Since the introduction of intracranial pressure monitoring, changes in intracranial pressure have been found in patients once signs of grade IV encephalopathy are established. 24 Nursing procedures, physiotherapy and postural change, as well as hypercapnia, may precipitate rises in intracranial pressure, but on many occasions no precipitating factor is apparent. When the pressure rises above 30 mmHg the clinical features of cerebral oedema, including abnormal pupillary responses, myoclonus or decerebrate posturing, are manifest. Papilloedema, bradycardia and hypotension develop at a late stage.
Previous reports of the use of mannitol and dexamethasone have failed to show benefit. However, a recent controlled trial comparing these two agents showed that dexamethasone was ineffective while mannitol reduced intracranial pressure in patients with normal renal function, reversed clinical features of cerebral oedema and was associated with an improvemen t in survival. 25 Intracranial pressure monitoring, early detection of cerebral oedema and treatment with mannitol Ig/kg intravenously over half an hour every four hours seems one area where a small advance in management of FHF may be achieved.
Circulatory failure
In general cardiac output is high in FHF reflecting low-peripheral resistance and increased arteriovenou s sh un ting. 26 Hypotension which cannot be explained by haemorrhage, fluid depletion, cardiac arrhythmia or failure is common. Due to the already elevated cardiac index, inotropic drugs (dopamine, dobutamine) are usually inappropriate and vasoconstrictors (noradrenaline) may be used with caution, as serious reductions in renal, cerebral or splanchnic blood flow may occur.
Respiratory failure
Hyperventilation, hypoxaemia and hypocapnia occur in most patients with FHF. Chest radiographs were abnormal in over half of a series of 100 consecutive patients with FHF treated at the Kings College Hospital unit. 27 Lobar collapse, areas of consolidation and bronchopneumonia following aspiration were common. Noncardiogenic pulmonary oedema occurred in 37 patients. 28
Hypoglycaemia
Blood glucose concentrations below 3.5 mmolll (60 mg/dl) occur in about a half of patients with FHf2 9 and may be responsible for early deterioration in consciousness. Prompt recognition of this complication is important in view of the severe irreversible brain damage which it can cause. Large amounts of glucose (2.4 kg daily has been recorded) may be needed to prevent it. 30 Hypoglycaemia has been attributed to a combination of glycogen depletion as a result of prodromal anorexia exacerbated by hepatocellular necrosis, and hyperinsulinism as a consequence of decreased hepatic metabolism of insulin. 31 Concentrations of glucogenic amino acids in plasma are elevated together with blood lactate. 32 These two abnormalities in the face of hypoglycaemia suggest that decreased gluconeogenesis and also increased glycolysis play a role.
Intravenous dextrose infusions (usually 20OJo, 500 ml six hourly) are the mainstay of nutritional support in FHF, but frequent blood glucose measurements are required as this can fluctuate widely. Carbohydrate tolerance is impaired in severe acute hepatitis as a result of insulin resistance 33 and plasma levels of tricarboxylic acid cycle intermediates are abnormally high in FHF, 32 providing further evidence of deranged intermediary metabolism.
Electrolyte abnormalities
Abnormal plasma concentrations of sodium and potassium are common aDd require at least daily estimation. Hypokalaemia «3.5 mmolll) often occurs in the early stages and can be lifethreatening,34 with body stores of potassium depleted by as much as 500 mmol. Impairment of renal function predisposes to hyperkalaemia and intravenous administration of potassium must be cautious and carefully monitored. Hyponatraemia «130 mmolll) is common in the later stages of FHF and may be due in part to an intracellular shift of sodium caused by impaired Na/K A TPaseY It should therefore not be treated by administering sodium unless large amounts of fluid have been lost by gastric Anaesthesia and Intensive Care, Vol. 13 aspiration or diarrhoea and ascites or oedema are absent. Hypernatraemia (>150 mmolll) ma~ als~ occur. 34 Infusions of plasma, high sodIUm Intake, negative fluid balance and osmotic diuresis due to hypertonic dextrose may all contribute. Plasma zinc concentrations fall progressively after the onset of grade IV encephalopathy (and urinary zinc is elevated) but the significance of the observation is unknown. 36 
Acid-base disturbances
Alkalosis is a common finding in FHF. In one series 60OJo of cases of alkalosis were respiratory in origin. 32 It is often associated with hyperventilation, hypocapnia and reduced cerebral perfusion and oxygen consumption. Metabolic alkalosis occurring early in the illness may be due to hypokalaemia or a failure of urinary alkalinisation (as urinary pH is often inappropriately low) and gastric aspiration may aggravate this at a later stage. Other potential causes of metabolic alkalosis include intravascular accumulation of basic compounds and movement of hydrogen ions into the intracellular space. Metabolic acidosis with lactic acidosis is uncommon and in the Kings College series was associated with hypotension, dehydration, peripheral vasoconstriction and hypoglycaemia following paracetamoloverdose.
Renal failure
Renal dysfunction develops in the majority of patients with FHp34 and is associated with a poor prognosis. Acute tubular necrosis is present in about half of the cases and may be distinguished from functional renal failure with reduced renal blood flow by simple microscopic and biochemical tests on the urine (Table 6 ). 
Coagulation defects and bleeding
Impaired coagulation is the rule in FHF. It is due mainly to inadequate synthesis of coagulation factors 11, V, VII, IX and X by the liver, tends to occur early and indicates severe damage. Clark et al. 37 found that coma only occurred in patients whose prothrombin time ratio exceeded 2.2 (normal <1.4). A minor degree of disseminated intravascular coagulation is common and contributes to thrombocytopenia and hypofibrinogenaemia, but plasma and heparin therapy is hazardous rather than beneficial. 38, 39 Massive transfusion of stored bank blood, low in coagulation factors and platelets, may aggravate the coagulopathy.
Bleeding may occur anywhere, including venepuncture sites, but gastrointestinal haemorrhage is the most important as it may be the cause of death. The usual source in FHF is acute erosions in the stomach and oesophagus (and rarely varices). Maintenance of intragastric pH at pH>4 or more by the use of the H2-receptor antagonist cimetidine has been shown to greatly reduce the incidence of gastrointestinal haemorrhage and should be started early in the course of the illness. 40 Coagulation tests do not predict which patients will bleed 39 and fresh frozen plasma, prothrombin extracts and platelets should be reserved until bleeding occurs.
Infection
Bacterial infections are an important cause of mortality in FHF, occurring in 10-25070 of patients. 41 ,42 In addition to the risk factors of coma and catheters, an increased susceptibility to infection is present. Reasons for this include defective classical and alternative pathways of complement,43, 44 defective opsonisation,43 diminished Kupffer cell clearance of aggregated albumin 45 as well as poor nutritional status.
Prophylactic antibiotic therapy increases the risk of Gram-negative skin colonisation 46 and should not be used. Antibiotics should be used only when there is clinical evidence of infection with fever and positive cultures.
Pancreatitis
Acute pancreatitis has been described as a major contributor to death in 5070 of one series of patients with FHF. 47 Milder attacks may occur more commonly but are difficult to diagnose, as abdominal pain and a raised serum amylase may occur in the absence of acute pancreatitis. 48 Severe abdominal pain, hypotension, or fall in central venous pressure and serum amylase concentrations above 1000 somogyi units are strong pointers to the diagnosis. Treatment is supportive and usually conservative.
Hypothermia
Hypothermia due to poor central temperature control in a comatose patient is a common terminal event, and may depress conscious state further. The second aspect has been considered above in relation to the individual complications, and good intensive care of these is the key to survival. Despite the best possible supportive care, it is not surprising that in the face of the complexity of complications death rates remain high. Treatment has run the gamut from the rational to the last resort, and many an optimistic anecdote has been later demolished by a controlled trial.
Treatment of specific disease Viral hepatitis:
In patients with viral hepatitis the development of serological markers for hepatitis A (IgM anti-HA V) and hepatitis B (lgM anti-HBc) has allowed early identification of these aetiological agents, as well as delta agent and presumed non-A non-B.
This information is important prognostically (as indicated above fatality rates are lower for hepatitis A) 'and may be important in treatment.
Specific therapy for fulminant viral hepatitis has been disappointing. Both high-dose anti- HBS serum and corticosteroids have been shown to be ineffective. In a co-operative double-blind, placebo-controlled trial involving 53 patients in 28 American hospitals, administration of hepatitis B antibody had no effect on survival and did not abolish antigenaemia. 49 Controlled trial of corticosteroids both in conventional and massive doses has shown them to be of no benefit in severe acute viral hepatitis 50 or fulminant hepatic failure. 51 , 52 In fact these combined results show a trend for increased mortality in corticosteroid-treated patients ( Table 7) . The use of interferon as an antiviral agent is one other possible approach to patients seen early in the course of viral hepatitis. In one report the natural interferon system was impaired in six patients with fulminant viral hepatitis, and three of five patients treated with exogenous human interferon survived to leave hospital. 53 In passing, the issue of immunoprophylaxis of viral hepatitis should be mentioned. The difficulty of treating severe hepatitis B infection makes prevention doubly important, particularly in groups at high risk of viral contact. If needles tick innoculation accidentally occurs from a patient who is HbsAg positive, then passive 'immunotherapy by injection of hepatitis B immunoglobulin (HBIg, 4 ml within 48 hours) should be followed by rapid commencement of a course of active hepatitis B vaccination. Paracetamol poisoning: Various antidotes, N-acetylcysteine being the most commonly used, have conclusively shown to prevent paracetamol toxicity by acting as glutathione precursors. Prescott had provided an excellent review of the subject. 7 Cysteamine, methionine and N-acetylcysteine are only effective if given within 8 to 10 hours; treatment after 15 hours is of no benefit. Cysteamine has long been abandoned because of its toxicity and oral methionine is unreliable in patients who are often nauseated. N-acetylcysteine has the advantage of being given intravenously and is currently the treatment of choice. The treatment regimen (Table 8) is indicated in all pa tien ts wi th plasma paracetamol concentrations above the 'treatment line' (see under aetiology). Treatment must be started as soon as possible while awaiting the laboratory result.
Temporary liver support
A number of different techniques have been used to try to remove toxic substances or replace some of the normal constituents of blood, usually synthesised by the liver. None of these treatments has yet been conclusively shown to improve survival. Many are heroic and expensive and in assessing uncontrolled reports it has to be remembered that in some series 30-40070 of patients may survive with good supportive treatment. 54, 55 Haemodialysis: In conventional form this offers little value, removing only urea and small amounts of ammonia and other small watersoluble molecules. A further development has been the use of a large-pore> polyacrylonitrile 23 , 56 Exchange transfusion, plasmaphoresis, total body washout: Despite initially encouraging reports 57 exchange transfusion has not been shown to increase survival. 55 In one controlled trial, all eight patients who received one or two six-litre exchanges died, while nine out of 13 patients given supportive therapy survived. 58 A few patients have been treated by plasmaphoresis 59 or total body washout 60 but the results do not suggest a major advance and each has been abandoned. Extracorporeal liver perfusion: Crosscirculation of patients' blood through volunteer human subjects has been tried with little success and is difficult to justify ethically. Perfusion of patients' blood through animal liver, either isolated or whole animal, has produced transient clinical and -biochemical improvement, but increased survival has not been proven. 55, 61 Artificial liver support: The rationale for this approach depends on removal of hypothetical circulating toxins by adsorption to activated charcoal or other resins. The initial use of charcoal haemoperfusion was associated with significant platelet activation and loss with due haemorrhagic consequences. 62 , 63 Subsequent studies by the Kings College Hospital group showed that a concomitant infusion of prostacyclin, PGI2, 16 ng/kg could prevent platelet activation, prevent platelet loss and reduce release of the platelet specific protein B thromboglobulin. 64 Evaluation of the compound charcoal-PGl2 treatment in 76 patients has produced very encouraging results. 65 The patients were given a total of 198 periods of perfusion with a mean duration of 4.9 hours. Of the 76 patients, 31 were first treated in grade III encephalopathy; and of these, 20 (65%) survived to leave hospital, a much better rate than the nine of 45 patients (20%) not treated until grade IV encephalopathy had already developed. Nonetheless, all patients ultimately developed grade IV encephalopathy, but fewer of the patients first per fused in grade III developed cerebral oedema. Animal studies from Chang and his colleagues using a galactosamine hepatitis model of FHF also confirm increased surviv2.1 following charcoal haemoperfusion, but only when this was performed before the animals developed deep coma. 66 Orthotopic liver transplantation Improved survival of patients undergoing hepatic transplantation -more than 50% at one year in major centres 67 -makes this technique worthy of careful clinical consideration. Its major role at present is in the management of chronic liver disease. The massive logistic effort that is required to prepare a patient for transplantation prevents its use in an acute and rapidly fatal illness like FHF unless techniques of liver support (such as charcoal haemoperfusion and correction of the haemorrhagic diathesis) reliably prevent complications. An adequate supply of donor organs is the other essential. Despite the severity of clinical and biochemical derangements in FHF, case reports from the Kings College Hospital group show that liver transplantation can be performed on patients in grade IV encephalopathy. 6, 67 They also describe a group of patients with subacute hepatic failure, in whom the development of encephalopathy was delayed, occurring more than eight weeks after the onset of symptoms, but who also had a high mortality and high incidence of complications. Two of these patients, aged 11 and 46, with presumed non-A non-B hepatitis and illnesses of four and six months duration were successfully grafted, although repeat transplantation was necessary in both.
PROGNOSIS
As already indicated, the immediate prognosis in FHF is poor, with survival in different series ranging from 10% to 40%. The variability of the syndrome makes it difficult to forecast the outcome in individual patients until the clinical signs of secondary organ failure have become established. Increasing coma is an important guide ( Table 5 ) but even profound coma with decerebrate posturing has been found in patients who eventually recovered.
There is little information on the long-term outlook in those who recover from FHF. In the majority the liver probably returns to normal, with cirrhosis or chronic hepatitis occurring in occasional patients. 68 
